We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

4,100
Open access books available

116,000
International authors and editors

125M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
From Sarcopenia to Frailty: The Pathophysiological Basis and Potential Target Molecules of Intervention

Zhuowei Yu, Qingwei Ruan, Grazia D’Onofrio and Antonio Greco

Abstract

Skeletal muscle is not only an endocrine organ but also one of core components of musculoskeletal system. Sarcopenia refers to a decline in the skeletal muscle mass and function. The former involves the size and number of changes in two types of myofibers, lower satellite cell density, and regeneration ability. The latter shows a loss of muscle strength. Frailty is a geriatric syndrome with multisystem impairment associated with increased vulnerability to stressors. Sarcopenia increases the risk of frailty and may be one of the major causes of physical frailty phenotype. Sarcopenia is also potentially associated with cognitive frailty phenotype. Aging might be the common underlying pathophysiology of sarcopenia and frailty. Therefore, there are some potential target molecules in aging-related signaling pathways that might be associated with sarcopenia and frailty. Nevertheless, sarcopenia can mediate metabolism and promote accelerate systemic aging, frailty, and age-related diseases by myokines in an endocrine manner. Lifestyle interventions (resistance exercise and dietary restriction) of gerontoscience are effective in the prevention of sarcopenia. Some pharmacological agents are registered in different phases of clinical trials for sarcopenia intervention. Phytochemicals, mTOR inhibitors, metformin and acarbose, NAD precursors, and sirtuin activators demonstrated that multiple target antiaging effects might also have preventive and therapeutic perspectives on sarcopenia and frailty.

Keywords: sarcopenia, physical frailty, cognitive frailty, aging

1. Introduction

Sarcopenia and frailty are two common geriatric conditions that may co-occur within a single individual with aging. Frailty is a heterogeneous clinical condition depended on different domains.
Definitions of frailty include Fried physical frailty phenotype (weight loss, exhaustion, physical inactivity, handgrip strength, and walk time) [1] and frailty index (use of walking aid, activities of daily living, incontinence, cognitive impairment, and multiple other components) [2]. Cognition performance decline is considered as a domain in Frailty index, but as “cognitive frailty” phenotype when physical frailty and potentially reversible cognitive impairment simultaneously occur [3]. Sarcopenia refers to decline in skeletal muscle mass and function, which includes primary sarcopenia, or age-related loss of muscle mass and function decline, and secondary sarcopenia resulting from nutrition, activity, and disease-related loss of muscle mass [4]. Sarcopenia is different from cachexia, which combines the loss of both muscle and fat. Obviously, physical frailty and sarcopenia share the core components, physical function impairment (weakness, slow walking speed, and balance problems), and sarcopenia is considered as the biological substrate and the pathway of physical frailty development [5, 6].

Although it is a controversy, sarcopenia and frailty are two separate conditions based on their definitions, and outpatients with sarcopenia were more likely to be more frail than frail outpatients to be sarcopenic [7]. Skeletal muscle is not only a component of musculoskeletal system but also an endocrine organ. Two components of sarcopenia also obviously contribute to frailty, a geriatric syndrome that has been defined as a multisystem impairment characterized by decreased reserve associated with increased vulnerability to stressors. First, the loss of muscle mass plays a critical role in unintentional weight loss of frailty in the elderly. Second, age-related loss of muscle strength, commonly referred as dynapenia, was associated with both sarcopenia and frailty [8]. Sarcopenia and frailty had the sensitivity and specificity for dynapenia of 33 and 89%, 17 and 98%, respectively. A longitudinal aging study with 731 community-dwelling older people demonstrated that dynapenia was related to the cognitive impairment [9]. Thus, dynapenia is also the important factor responsible for frailty. Moreover, muscle cross-talks with other tissues and organs by myokines in an endocrine manner to mediate metabolism and promote aging, diseases, and frailty. Here, we review the epidemiological evidence and pathophysiological basis of skeletal muscle aging, or primary sarcopenia, that result in frailty and potential target molecules of intervention. Particularly, we focus on the pathophysiological basis of sarcopenia, including age-related changes of nutrient and stress sensors, positive and negative regulators of muscle growth, and the maintenance of muscle mass and function. Moreover, we also summarize the underlying mechanisms of sarcopenia accelerating systemic aging, frailty, and age-related diseases. Finally, we looked for the potential target molecules of intervention of sarcopenia according to the pathophysiological basis and relevant signal pathways.

2. From Sarcopenia to frailty: the pathophysiological basis

2.1. From sarcopenia to physical and cognitive frailty: the epidemiological evidence

Frailty is heterogeneous and contains physical and cognitive multiple domains. In this context, the concept of “Cognitive frailty” becomes essential. It refers to simultaneous presence of physical frailty and potentially reversible cognitive impairment but without dementia [3]. Cognitive frailty includes reversible and potentially reversible subtypes [10] and may represent
a precursor of neurodegenerative processes [10]. The link between physical function and cognitive decline provides important targets to develop effective preventive strategies in earlier cognitive impairment stages [3, 11, 12].

Epidemiological studies suggested that sarcopenia increases the risks of both physical frailty and cognitive impairment. Loss of muscle mass and strength is associated with increased dependence, frailty, and mortality. Low appendicular lean mass related to body mass index could detect patients at risk for frailty [13]. A cross-sectional study with small subjects, 273 Japanese community-dwelling older women aged >65 years showed that sarcopenia was related only with prefrailty and frailty, and cognitive decline was related to frailty [14]. However, several studies showed an association between sarcopenia parameters and cognitive impairment. Low handgrip strength was shown to correlate with a decrease in Mini Mental State Examination (MMSE) score [15]. Other studies also reported an association between handgrip strength and the risk of Alzheimer disease and the rate of cognitive decline [16–18]. In prospective studies, a decrease in physical performance in relation to future dementia was demonstrated [19, 20]. Subjects aged >65 years who scored low in a physical performance test had a three-times higher risk of developing dementia at a 6-year follow-up [21]. Recently, the new concept of “Motoric Cognitive Risk (MCR) syndrome” was defined as having mild cognitive impairment (MCI) and slow gait, supporting the common underlying mechanism in physical and cognitive impairment [22]. MCR offered further benefit on predicting dementia than MCI or slow gait alone. A recent study demonstrated an association between increased risk of cognitive impairment, mainly MCI, and poor lower extremity function [21].

2.2. Aging promotes sarcopenia and frailty

Factors relating to skeletal muscle mass and strength changes include the loss of motor units innervating muscle, age-related hormone changes, muscle hypoxia resulting from atherosclerosis and chronic proinflammatory status, decreased physical activity and protein intake, age-related insulin resistance, and mitochondrial dysfunction [23]. Aging leads to a preferential reduction of type II myofiber size. There is a significant loss of type II muscle fibers, lower satellite cell density, and lower satellite cell/fiber ratio in older individuals with sarcopenia [24]. The loss of motor units innervating muscle, especially type II myofibers [25], and the decreased blood flow to muscle [26] results in the loss of muscle mass. Meanwhile, many elderly population with insulin resistance who maintains the sensitivity of glucose metabolism, but not protein synthesis, show age-related anabolic resistance, meaning the reduced muscle protein synthesis [27, 28]. However, muscle of older individuals with type 2 diabetes [29] metabolic syndrome [30] demonstrated a significant low proportion of type I fibers that is positively associated with the severity of insulin resistance. Thus, the loss of muscle mass and the alterations of myofiber type proportion due to insulin resistance could potentially affect whole body glucose homeostasis [31]. Age-related hormone changes, for example, the decline of anabolic hormone testosterone leads to the loss of both muscle mass and strength [32]. The decline in both growth hormone and insulin-like growth factor 1 are related to the loss of muscle mass but not muscle strength [33]. Muscle hypoxia results from atherosclerosis and chronic proinflammatory status leads to the loss of both muscle mass and strength [25]. Other factors, decreased physical activity and protein intake, also involve in the loss of muscle mass.
Age-related decline of the levels of 25(OH) vitamin D due to a decreased production of 25(OH) vitamin D in skin or a decline in vitamin D absorption can result in the decline of muscle function [25]. Age-related insulin resistance causes an increase of fat infiltration into muscle and a decline in muscle strength [34]. Mitochondrial dysfunction in aging skeletal muscle causes oxidative damage and the decline of energy generation to maintain function properly [35].

The biological mechanisms underlying the association between sarcopenia and frailty are uncertain [36]. Any plausible explanations are that physical, motor, and cognitive functions are not causally related but are affected by common underlying pathophysiology [37]. Frailty, cognitive impairment, and sarcopenia share many common risk factors, such as immune or inflammatory response, oxidative stress, and hormonal dysregulation [38, 39]. In view of this, frailty, cognitive impairment, and sarcopenia may be highly interrelated [38, 40]. Inflammatory markers such as C-reactive protein and interleukin-6 concentrations are correlated negatively with muscle strength and physical performance [41, 42]. According to the definition of cognitive frailty, physical factors are the potential causes of cognitive impairment. In a study, high levels of these markers are associated with a 66% increase in cognitive impairment risk at 4-year follow-up in elders with metabolic syndrome [43]. Elevated oxidative stress [44], decreased sex steroid levels [45, 46], and insulin resistance [47, 48] are also involved in the association between physical and cognitive dysfunction.

2.3. The maintenance of muscle mass and function

The maintenance of normal muscle mass and function depends on the dynamic balance between positive and negative regulators of muscle growth. Muscle growth promoters include follistatin (FST), bone morphogenetic proteins (BMPs), brain-derived neurotrophic factor (BDNF), and irisin. Muscle growth suppressors contain myostatin, transforming growth factor beta (TGFβ), activins A and B, growth, and differentiation factor-11 and -15 [49, 50]. Age-related changes of these molecules, together with other factors, such as age-related diseases, chronic low-grade systemic inflammation, insulin resistance, endocrine aging, low physical activity, aging-related impairment of neuromuscular junction dysfunction, and contractile insufficiency because of skeletal muscle-specific troponin T leakage from sarcomere, result in imbalance between positive and negative regulators of muscle growth and sarcopenia development [49]. Muscle growth suppressors through the antibody-coupled, T-cell receptor/anaplastic lymphoma kinase 4,5 (ActR/Alk 4,5), or type I and II TGFβ receptor (TβRI and TβRII), phosphorylate mothers against decapentaplegic homolog 2/3 (SMAD 2/3), then combine SMAD 4 and inhibit the activation of an alternative pathway/mammalian target of rapamycin (Alt/mTOR) signal. TGFβ promotes SMAD3 binding to the promoters of both fibronectin type III domain containing 5 (FNDC5) and procaspase-activating compound 1α (PAC-1α), and suppresses the expression of irisin and PAC-1α [51]. The elevated growth differentiation factor 11 (GDF11) increases the risk for age-related frailty and comorbidities [50]. Muscle growth promoters through their receptors phosphorylate SMAD 1/5/8 decrease the inhibition of Alt/mTOR signal and maintain muscle mass and strength. Insulin resistance due to aging, obesity, and diabetes results in the suppression of insulin/insulin-like growth factor-1/phosphatidylinositol 3-kinase/protein kinase B (IGF 1/PI3K/AKT)/mTOR, and muscle hypotrophy and dysfunction of metabolism;
the less activated Alk fails to block the nuclear translocation of Foxo 3 to enhance the expression of autophagy-related genes and the consequent protein degradation [31, 52].

2.4. Sarcopenia accelerates systemic aging, frailty, and age-related diseases

Skeletal muscle influence systemic aging and lifespan by nutrient and stress sensors and myokines [53]. DNA damage and mutations are particularly prominent in aging skeletal muscle. Overexpression of phosphoenolpyruvate carboxykinase (PEPCK-C) and mitochondrial uncoupling proteins delays reproductive aging and decreases the incidence of several age-related diseases. Nutrient and stress sensors in sarcopenia include decreased sirtuin 1 resulting from low nicotinamide adenine dinucleotide (NAD)+ synthesis and high NAD+ consumption and low adenosine monophosphate-dependent protein kinase (AMPK) activity, which results in the decline of the activity of peroxisome proliferator-activated receptor gamma coactivator-1a (PGC-1a) [54, 55]. The overexpression of AMPK and PGC-1a in muscle not only delays the age-related muscle deterioration but also slows the functional decline of other tissues, delay age-related metabolic defects, including systemic low-grade chronic inflammation, insulin resistance, increase in the stress resistance of the organism and extend lifespan. The other two nutrient sensors, insulin/insulin-like growth factor (IIS) and mTOR signaled nutrient abundance (high fat, amino acids, and sugar diet) and anabolic activity, are major accelerators of aging. mTOR inhibition by rapamycin or mTORC1 activity inhibition by genetic modification, and the downregulation of mTORC1/ribosomal protein S6 kinase beta-1 (S6K1) increases lifespan in mammals [55]. The decrease in regenerative capacity and skeletal muscle loss with age coincides with suppression of IIS pathways which is an attempt to promote longevity of the organism and survival within the tissue [56]. Age-related sarcopenia is associated with an increase in abdominal obesity, which refers to sarcopenic obesity [57]. Sarcopenic obesity leads to the infiltration of fat into the muscle and the accumulation of triglycerides within the cell, which impairs the function of the insulin receptor substrate causing insulin resistance, a lower lipid buffering capacity, and anabolic resistance in muscle [23, 58]. Sarcopenic obesity also results in cognitive impairment because of insulin resistance. In a cohort of 1570 older British men, compared with participants in the normal cognitive aging group, those elder men with severe cognitive impairment were more likely to be sarcopenic, with waist circumference >102 cm, BMI >30 kg/m² and to be in the upper quintile of total fat mass, central fat mass, peripheral fat mass, and visceral fat level after age-adjusted multinomial logistic regressions [59]. In experiment animal mouse, obesity in combination with sarcopenia exacerbates blood-brain barrier disruption, neuroinflammation, and oxidative stress of hippocampus, which likely contribute to the remarkable cognitive decline [60]. Calorie restriction and exercise increase the concentrations of metabolic effectors NAD+ and AMP but reduce the concentrations of the hormonal effectors IIS and growth hormone. Meanwhile, these interventions also decrease the levels of glucose, amino acids, and lipids, recover downstream activity, such as DNA repair, mitochondrial biogenesis, and function, promote homeostasis, decrease frailty and comorbidities.

Beyond the profound influence on systemic aging and body metabolism, muscle secrete myokines, which act on muscles and other tissues, such as adipose, bones and brain in an autocrine, paracrine, and endocrine fashion [61]. The metabolites released from muscle and the interactions
between muscle and nerve also participate in the systemic effects of muscle on the organism’s physiology. Exercise can activate PGC-1α/FNDC5 pathway, promote myokine irisin secretion, induce hippocampal BDNF release, and improve cognitive function [62].

3. From sarcopenia to frailty: the potential target molecules of intervention

The major causes of frailty include chronic diseases, such as congestive heart failure, diabetes, chronic obstructive pulmonary disease (COPD), anemia, polymyalgia rheumatic, and endocrine disorder; decreased nutrient intake because of anorexia resulting from social factors, decline in taste and smell, altered fundal compliance, enhanced release of cholecystokinin, increased leptin and cytokines, sarcopenia, and pain [63]. Treating the chronic diseases can reverse the loss of muscle mass and frailty, such as with angiotensin-converting enzyme inhibitors in some patients with congestive heart failure, both erythropoietin and darbepoietin-α in the individuals with anemia, and vitamin B12 supplementation in acrocytic anemia and related cognitive impairment. Lifestyle interventions play critical roles in the prevention of sarcopenia, frailty, and cognitive impairment. Physical exercise, particularly resistance exercise, can improve muscle mass and strength in the elderly [64, 65] and obese elderly [58]. Individuals with higher initial adiposity experience less improvement in both muscle strength and physical function [66]. Moreover, the addition of caloric restriction during resistance training improves mobility and does not compromise other functional adaptations to resistance training [66]. Resistance training also can increase circulating irisin [67] and improve cognitive performance [62]. In addition, physical exercise and caloric restriction can benefit age-related insulin resistance, reduced mitochondrial biogenesis, and failure of autophagy [68]. However, it is undesirable to use caloric restriction alone in sarcopenic elderly, which results in further loss of lean tissue mass. The oldest olds also with anabolic resistance and frailty find it difficult to perform resistance exercise to achieve benefit effects.

Dietary interventions including protein intake, antioxidants, and vitamin D fortification may benefit the conditions of sarcopenia and frailty. Protein supplies the amino acids, especially leucine, which may activate the signaling pathways required for muscle synthesis. Vitamin D deficiency is common in individuals with sarcopenia, frailty, and cognitive impairment. However, the effects of both protein supplementation and vitamin D intervention on muscle strength and physical performance have mixed results [69]. Although individuals with higher overall antioxidant status have better physical function, such as walking speed [70], antioxidant interventions might not attenuate, and even aggravate sarcopenia due to the health-promoting action of reactive oxygen spices [71].

There are no licensed treatments for sarcopenia and frailty. Pharmacological agents proposed and focused by investigators, with potential for treating sarcopenia include the myostatin signaling pathway and hormone replacement therapy (Table 1), currently are at various stages of development [72]. Myostatin, the family member of TGF-β, is a skeletal muscle-specific myokine. Myostain binding with activin type IIB receptor inhibits myoblast proliferation, muscle
strength, and mass by negative regulation of mTOR signaling [73]. Myostatin inhibition by activin receptor trap or inhibitor and myostatin antibody might be useful agent for the treat-
ment of human muscle degenerative diseases (Table 1) [72]. Testosterone supplementation is another major focus for drug discovery of sarcopenia. Testosterone could increase both muscle mass and strength in men but are linked to adverse cardiovascular events with short durations of therapy [74, 75]. In order to decrease the side effects of testosterone, the selective androgen receptor molecules, including steroids and nonsteroids, have been developed, and some are at phase 3 (Table 1). Tirasemtiv is a fast skeletal troponin activator that sensitizes the sarcomere to calcium and amplifies the function of muscle in neuromuscular diseases, such as Amyotrophic Lateral Sclerosis and myasthenia gravis (Table 1) [76, 77].

Age is the greatest risk factor for nearly every major cause of mortality in developed nations [78] and the profound effect of aging on sarcopenia, frailty, and cognitive impairment is often overlooked. A number of aging-associated molecular signals might be the potential target in the prevention and treatment of sarcopenia, frailty, and cognitive impairment. Genetic or pharmacological regulation of NAD+/Sirt1, sestrins/AMPK/PGC1α, IGF-1/Akt/mTOR, TGF-β, myostatin, activins, GDFs /SMAD2/3, BMPs/SMAD1/5/8 signal molecules, myokine irisin and FGF21, the antagonist of myokine myostatin propeptide follistatin or follistatin-like 3, and urocortins can not only improve muscle mass and/or function but also delay frailty and age-related diseases [31, 54, 68]. Besides dietary restriction and exercise, geroscience interventions with translational potential include mTOR inhibitors, metformin and acarbose, NAD precursors and sirtuin activators, modifiers of senescence and telomere dysfunction, hormonal and

<table>
<thead>
<tr>
<th>Mechanism of action</th>
<th>Drug name</th>
<th>Drug developer</th>
<th>Indication sought</th>
<th>Study phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Myostatin antagonists</td>
<td>Activin receptor trap</td>
<td>ACE-031</td>
<td>Acceleron</td>
<td>Duchenne muscular dystrophy</td>
</tr>
<tr>
<td></td>
<td>Myostatin antibody</td>
<td>REGN-1033</td>
<td>Regeneron/Sanofi</td>
<td>Sarcopenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LY-2495655</td>
<td>Eli Lilly</td>
<td>Hip arthropasty</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PF-06252616</td>
<td>Pfizer</td>
<td>Elderly fallers</td>
</tr>
<tr>
<td></td>
<td>Activin receptor inhibitor</td>
<td>Bimagrumab (BMY338)</td>
<td>Novartis</td>
<td>Inclusion body myositis</td>
</tr>
<tr>
<td>II. Selective androgen receptor modulators</td>
<td>Enobasarm (ostarine)</td>
<td>GTx</td>
<td>Cancer cachexia</td>
<td>Phase 3 (did not meet primary endpoint)</td>
</tr>
<tr>
<td>III. Skeletal troponin activators</td>
<td>Tirasemtiv</td>
<td>Cytokinetics</td>
<td>Amyotrophic lateral sclerosis myasthenia gravis</td>
<td>Phases 2 and 3</td>
</tr>
</tbody>
</table>

Table 1. Pharmacological agents in development with potential for treating sarcopenia [72].
circulating factors, and mitochondrial-targeted therapeutics [78]. Phytochemicals obviously are ideal geroscience interventions with translational potential. They not only have multiple target molecules in many aging-related signalling pathways, such as sestrins/AMPK/PGC1α, IGF-1/Akt/mTOR, against chronic inflammation and oxidative stress but also have systemic influence with low side effects, including skeletal muscle and other domains of frailty [79, 80].

4. Conclusion and perspective

Sarcopenia is one of the important causes of physical frailty. Frailty contains different phenotypes, such as physical frailty and cognitive frailty or multiple domains in frailty index. Skeletal muscle influences body metabolism, systemic aging, accelerates physical frailty, cognitive impairment, and decrease healthy lifespan. Individuals with primary sarcopenia have an increase in the risk for frailty, cognitive impairment, and age-related diseases. Aging might be the common mechanism of sarcopenia, frailty, and cognitive impairment. Cognitive frailty is an important target of the prevention for both physical and cognitive disability [81]. Although some pharmacological agents are registered in different phases of clinical trials for sarcopenia intervention, no drug is really used for the clinical treatment of sarcopenia. Phytochemicals have effects on multiple targets of aging-related signaling pathways, and other targeted aging molecules, such as mTOR inhibitors, metformin and acarbose, NAD precursors, and sirtuin activators [78, 82], have preventive and therapeutic perspectives on sarcopenia, frailty, and age-related diseases.

Acknowledgements

This work was supported by grants from the Shanghai Hospital Development Center (No. SHDC12014221), Shanghai Municipal Commission of Health and Family Planning, Key developing disciplines (2015ZB0501).

Author details

Zhuowei Yu1,2, Qingwei Ruan1,2*, Grazia D’Onofrio3 and Antonio Greco3

*Address all correspondence to: 13661717346@163.com

1 Shanghai Institute of Geriatrics and Gerontology, Shanghai Key Laboratory of Clinical Geriatrics, Huadong Hospital, Shanghai, China

2 Research Center of Aging and Medicine, Shanghai Medical College, Fudan University, Shanghai, China

3 Department of Medical Sciences, Geriatric Unit & Laboratory of Gerontology and Geriatrics, IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, Foggia, Italy
References


[8] Iwamura M, Kanauchi M. A cross-sectional study of the association between dynapenia and higher-level functional capacity in daily living in community-dwelling older adults in Japan. BMC Geriatrics. 2017;17:1


between two operational definitions of sarcopenia-data from the Berlin Aging Study II (BASE-II). The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2015;70(6):779-784


[57] Jura M, Kozak LP. Obesity and related consequences to ageing. AGE. 2016;38:23


[76] Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI; Tirasemtiv in Myasthenia Gravis Study Group. A double-blinded, randomized, placebo-controlled trial to evaluate efficacy, safety, and tolerability of single doses of tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis. Neurotherapeutics. 2015;12(2):455-460


